Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Benitec Biopharma Inc.NASDAQ: BNTC
Cash & Equivalents · Q3 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 78.4% from a year ago
Cash & equivalents stood at $184.76M at the end of Q3 FY2026, up 78.4% from a year earlier and down 2.1% from the prior quarter. Over 3 fiscal years it compounded at +188.7% a year.
Context
- Cash & equivalents amounted to 98.8% of total assets at the end of Q3 FY2026, up 0.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +78.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 97.74M USD
- Year-over-year change
- +92.2%
- 4-year CAGR
- +49.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 97.74M | +92.2% |
| FY2024 | 2024-06-30 | 50.87M | +1953.5% |
| FY2023 | 2023-06-30 | 2.48M | -39.0% |
| FY2022 | 2022-06-30 | 4.06M | -79.5% |
| FY2021 | 2021-06-30 | 19.77M | — |
Cash & Equivalents vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 cash & equivalents of $184.76M is the 3rd highest of the 10 companies compared; the peer median is $94.46M.
- Its year-over-year change of +78.4% is the 2nd highest of 10, against a peer median of +4.6%.
- Cash & equivalents amounts to 98.8% of total assets for BNTC, versus a peer median of 47.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $297.74M | +41.4% | -27.2% | 70.4% | |
| Dec 2025 | $254.07M | -9.5% | +19.2% | 47.5% | |
| Mar 2026 | $184.76M | +78.4% | +188.7% | 98.8% | |
| Mar 2026 | $130.93M | +36.7% | -35.2% | 24.8% | |
| Mar 2026 | $124.16M | +75.4% | +8.2% | 47.2% | |
| Mar 2026 | $94.46M | +4.6% | +12.8% | 34.7% | |
| Mar 2026 | $36.2M | -2.9% | -36.5% | 17.0% | |
| Mar 2026 | $35.94M | -24.9% | +53.2% | 32.8% | |
| Mar 2026 | $31.86M | -15.7% | -37.9% | 56.0% | |
| Mar 2026 | $14.11M | +89.9% | -1.6% | 89.5% | |
| Peer median (excluding BNTC) | $94.46M | +4.6% | -1.6% | 47.2% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.